From the Journals

ICYMI: MRI-based treat-to-target approach offers no benefit for RA patients

Publish date: February 5, 2019
By
Lucas Franki

 

FROM JAMA

Patients with RA in clinical remission who received an MRI-based treat-to-target strategy did not achieve superior disease activity remission rates (85% vs. 88%) or reduced radiographic progression (66% vs. 62%), compared with a conventional treat-to-target strategy, according to results of the Danish, 2-year, investigator-initiated, randomized, multicenter IMAGINE-RA trial published in JAMA (2019 Feb 5. doi: 10.1001/jama.2018.21362).

We covered this study at the 2018 European Congress of Rheumatology before it was published in the journal. Read the story at the link above.

Recommended Reading

Drug-drug interactions in rheumatology patients on PPIs: An underappreciated problem?
MDedge Rheumatology
New insight gained into natural history of interstitial pneumonia with autoimmune features
MDedge Rheumatology
Jakinib explosion for RA: Where do they fit in clinical practice?
MDedge Rheumatology
Abatacept reduced infections in RA patients
MDedge Rheumatology
Blood test shows potential as an early biomarker of methotrexate inefficacy
MDedge Rheumatology
Treat-to-target approach for CVD risk factors decreased atherosclerosis in RA patients
MDedge Rheumatology
Women with RA have reduced chance of live birth after assisted reproduction treatment
MDedge Rheumatology
Stopping TNF inhibitors before 20 weeks’ gestation not linked to worsening RA, JIA
MDedge Rheumatology
Experts cite different approaches to try for methotrexate-related nausea, fatigue
MDedge Rheumatology
Findings in seropositive arthralgia patients may help to predict RA
MDedge Rheumatology